HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

DNA Topoisomerase IV (Topoisomerase IV)

A bacterial DNA topoisomerase II that catalyzes ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. Topoisomerase IV binds to DNA as a heterotetramer consisting 2 parC and 2 parE subunits. Topoisomerase IV is a decatenating enzyme that resolves interlinked daughter chromosomes following DNA replication.
Also Known As:
Topoisomerase IV; Topo IV; Topoisomerase IV Subunit A; Topoisomerase IV Subunit B; parC Gene Product; parC Gene Product, Topo IV; parE Gene Product; parE Gene Product, Topo IV; Topoisomerase IV, DNA; parC Protein; parE Protein
Networked: 29 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Álvarez-Hernández, Diego Abelardo: 1 article (10/2015)
2. Garza-Mayén, Gilda Sofía: 1 article (10/2015)
3. Vázquez-López, Rosalno: 1 article (10/2015)
4. Palmer, Tiffany: 1 article (08/2015)
5. Gao, Ning: 1 article (08/2015)
6. Doig, Peter: 1 article (08/2015)
7. Mills, Scott D: 1 article (08/2015)
8. Thresher, Jason: 1 article (08/2015)
9. Andrews, Beth: 1 article (08/2015)
10. Fan, Jun: 1 article (08/2015)

Related Diseases

1. Bacterial Infections (Bacterial Infection)
2. Gonorrhea
3. Infection
04/01/2011 - "CF-derived strains tend to harbour mutations in the efflux pump regulator nfxB, while non-CF strains tend to bear mutations in the efflux regulator mexR or in parC, which encodes one of two subunits of DNA topoisomerase IV. We suggest that differences in resistance mechanisms between CF and non-CF strains result either from local adaptation to different sites of infection or from differences in mutational processes between different environments. "
01/01/2015 - "A sitafloxacin regimen is highly effective on Mycoplasma genitalium infections, including those caused by the mycoplasmas harboring mutant topoisomerase IV with a quinolone resistance-associated amino acid change in ParC. "
08/01/2012 - "These compounds simultaneously inhibit DNA gyrase and Topoisomerase IV at similar nanomolar concentrations, reducing the likelihood of the spontaneous occurrence of target-based mutations resulting in antibiotic resistance, an increasing threat in the treatment of serious infections."
02/01/2006 - "The presence of fluoroquinolone resistance-associated mutations within the quinolone resistance-determining region of DNA gyrase and topoisomerase IV was investigated genetically in clinical isolates of Proteus mirabilis recovered from patients with urinay tract infections. "
10/01/2015 - "They directly inhibit DNA replication by interacting with two enzymes; DNA gyrase and topoisomerase IV. They have been widely used for the treatment of several community and hospital acquired infections, in the food processing industry and in the agricultural field, making the increasing incidence of quinolone resistance a frequent problem associated with constant exposition to diverse microorganisms. "
4. Urinary Tract Infections (Urinary Tract Infection)
5. Poisoning

Related Drugs and Biologics

1. DNA Topoisomerase IV (Topoisomerase IV)
2. DNA Gyrase
3. DNA (Deoxyribonucleic Acid)
4. DNA Topoisomerases
5. Ciprofloxacin (Cipro)
6. Fluoroquinolones
7. Enzymes
8. Quinolones
9. gemifloxacin (Factive)
10. GTP-Binding Proteins (G-Protein)

Related Therapies and Procedures

1. Therapeutics